Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Operating activities:
Net income	$ 744,204	$ 7,285,932
Reconciliation of net income to net cash provided by operating activities:
Depreciation and amortization	376,530	440,779
Change in fair value of stock warrants	4,394,778	(5,399,569)
Provision for sales returns	(26,120)	(222,764)
Write-off of inventories		867,316
Stock-based compensation expense	338,139	637,487
Gain on short-term investments	(16,997)
Loss on disposal of fixed assets	36,900	6,225
Changes in operating assets and liabilities:
Accounts receivable	(2,026,081)	(308,865)
Due from related party	1,294,491	(348,424)
Inventories	635,400	(938,288)
Prepaid expenses and other current assets	(547,306)	164,196
Other non-current assets	(86,016)	425,408
Accounts payable	95,482	(856,417)
Accrued expenses	(137,444)	(397,590)
Deferred revenue	(160,485)	(103,406)
Net cash provided by operating activities	4,915,475	1,252,020
Investing activities:
Purchase of property and equipment	(246,935)	(985,930)
Additions to short term investments		(179,811)
Cash paid for acquisition, net of cash received	(14,516,297)
Proceeds from the sale of short-term investments	15,353,744
Net cash provided by (used in) investing activities	590,512	(1,165,741)
Financing activities:
Redemption of series C convertible preferred stock		(50,000)
Proceeds from exercise of stock options	10,263
Principal payments on note payable	(7,297)
Dividends paid	(20,625)
Net cash used in financing activities	(17,659)	(50,000)
Effect of exchange rate changes on cash and cash equivalents	124,662	35,140
Net increase in cash and cash equivalents	5,612,990	71,419
Cash and cash equivalents, beginning of period	13,204,067	10,114,163
Cash and cash equivalents, end of period	18,817,057	10,185,582
Supplemental cash flow information
Cash paid for income taxes	2,876	52,728
Cash paid for interest	4,532
Supplemental noncash financing activities
Common stock issued in connection with the acquisition of Molecular Profiles	$ 8,105,700